 |
市场调查报告书
商品编码
1477229
1 型糖尿病市场，按设备类型、按胰岛素类型、按最终用户、按配销通路、按地理位置Type 1 Diabetes Market, By Device Type, By Insulin Type, By End User, By Distribution Channel, By Geography |
||||||
价格
简介目录
预计2024年全球1型糖尿病市场价值为159.5亿美元，预计到2031年将达到243.6亿美元，2024年至2031年年复合成长率(CAGR)为6.2%。
| 报告范围 | 报告详情 | ||
|---|---|---|---|
| 基准年： | 2023年 | 2024 年市场规模： | 159.5 亿美元 |
| 历史数据： | 2019年至2023年 | 预测期： | 2024年至2031年 |
| 预测 2024 年至 2031 年复合年增长率： | 6.20% | 2031 年价值预测： | 243.6 亿美元 |
图 1. 1 型糖尿病市场占有率 (%)（按地区），2024 年
1 型糖尿病是一种自体免疫疾病，胰臟产生很少或不产生胰岛素。它是由于胰臟中产生胰岛素的β细胞被破坏所造成的。胰岛素是一种调节血糖的荷尔蒙。如果没有胰岛素，葡萄糖就会留在血液中，无法当作能量。结果，血糖（糖）水平变高。 1 型糖尿病的症状包括口渴增加、排尿增加、食慾增加但体重减轻、视力模糊和疲倦。虽然第 1 型糖尿病无法治愈，但可以透过胰岛素治疗、饮食、运动和自我监测血糖水平来控制。全球 1 型糖尿病市场由用于监测和管理 1 型糖尿病患者血糖水平的设备和疗法组成。
市场动态：
全球 1 型糖尿病市场的成长主要是由全球 1 型糖尿病盛行率上升所推动的。根据美国疾病管制与预防中心2023 年11 月发布的新闻稿，到2021 年，将有170 万名年龄在20 岁或以上的成年人报告自己患有1 型糖尿病并使用胰岛素，占所有诊断为糖尿病的美国成年人的5.7%。人们对糖尿病管理和先进监测设备的认识不断提高正在推动市场成长。然而，胰岛素和其他管理疗法的高成本对市场成长构成了重大挑战。新技术带来的连续血糖监测设备的改进为持续的市场扩张提供了有利可图的机会。
研究的主要特点：
- 该报告对全球 1 型糖尿病市场进行了深入分析，并提供了以 2023 年为基准年的预测期（2024-2031 年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
- 它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
- 这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
- 它根据以下参数描述了全球 1 型糖尿病市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
- 该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
- 全球 1 型糖尿病市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
- 利害关係人可以透过用于分析全球 1 型糖尿病市场的各种策略矩阵轻鬆做出决策。
目录
第一章：研究目标与假设
- 研究目标
- 假设
- 缩写
第 2 章：市场范围
- 报告说明
- 市场定义和范围
- 执行摘要
- Coherent Opportunity Map (COM)
第 3 章：市场动态、法规与趋势分析
- 市场动态
- 司机
- 限制
- 市场机会
- 影响分析
- 市场走向
- 最近的发展
- 收购和合作场景
- 技术概览
- 监管场景
- 定价分析
- PEST分析
第 4 章：全球 1 型糖尿病市场 - 冠状病毒 (COVID-19) 大流行的影响
- 整体影响
- 政府倡议
- COVID-19 对市场的影响
第 5 章：2019 - 2031 年全球 1 型糖尿病市场（按设备类型）（十亿美元）
- 概述
- 胰岛素笔
- 胰岛素注射器
- 胰岛素帮浦
- 胰岛素喷射注射器
第 6 章：全球第 1 型糖尿病市场，按胰岛素类型，2019 - 2031 年（十亿美元）
- 概述
- 长效胰岛素
- 速效胰岛素
第 7 章：全球 1 型糖尿病市场，按最终用户划分，2019 - 2031 年（十亿美元）
- 概述
- 家庭护理设置
- 医院和诊所
- 学术及研究机构
- 其他的
第 8 章：全球 1 型糖尿病市场，按配销通路，2019 年 - 2031 年，（十亿美元）
- 概述
- 医院药房
- 零售药局
- 网路药局
第 9 章：2019 - 2031 年全球 1 型糖尿病市场（按地区）（十亿美元）
- 介绍
- 北美洲
- 我们
- 加拿大
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地区
- 欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 欧洲其他地区
- 亚太地区
- 中国
- 印度
- 日本
- 东协
- 澳洲
- 韩国
- 亚太地区其他地区
- 中东
- 海湾合作委员会
- 以色列
- 中东其他地区
- 非洲
- 北非
- 中非
- 南非
第 10 章：竞争格局
- 公司简介
- Biocon Ltd.
- Novo Nordisk
- Gan & Lee Pharmaceuticals
- Zealand Pharma
- AstraZeneca
- Eli Lilly and Company
- Sanofi
- Wockhardt Ltd.
- Ypsomed AG
- Novartis
- Panbela Therapeutics
- Diamyd Medical
- Adocia
- Anelixis Therapeutics
- Oramed Pharmaceuticals Inc.
第 11 章：分析师观点
- 命运之轮
- 分析师观点
- 连贯的机会图
第 12 章：参考文献与研究方法
- 参考
- 研究方法论
简介目录
Product Code: CMI6791
Global type 1 diabetes market is estimated to be valued at USD 15.95 Bn in 2024 and is expected to reach USD 24.36 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2023 | Market Size in 2024: | US$ 15.95 Bn |
| Historical Data for: | 2019 To 2023 | Forecast Period: | 2024 To 2031 |
| Forecast Period 2024 to 2031 CAGR: | 6.20% | 2031 Value Projection: | US$ 24.36 Bn |
Figure 1.Type 1 Diabetes Market Share (%), By Region, 2024
Type 1 diabetes is an autoimmune disease where the pancreas produces little or no insulin. It results from the destruction of insulin-producing beta cells in the pancreas. Insulin is a hormone that regulates blood sugar. Without insulin, glucose stays in the blood and cannot be used for energy. As a result, blood glucose (sugar) levels become high. Symptoms of type 1 diabetes include increased thirst, increased urination, weight loss despite increased appetite, blurred vision and tiredness. While there is no cure for type 1 diabetes, it can be managed through insulin therapy, diet, exercise, and self-monitoring of blood glucose levels. Global type 1 diabetes market consists of devices and therapeutics used for monitoring and managing blood glucose levels in type 1 diabetes patients.
Market Dynamics:
Global type 1 diabetes market growth is primarily driven by rising prevalence of type 1 diabetes across the world. According to Centers for Disease Control and Prevention press release published in November 2023, 1.7 million adults in 2021, aged 20 years or above which totals to 5.7% of all US adults with diagnosed diabetes reported that they have type 1 diabetes and use insulin. Increasing awareness regarding diabetes management and advanced monitoring devices are driving the market growth. However, high cost of insulin and other management therapies pose a major challenge to market growth. The improvements in continuous glucose monitoring devices enabled by new technologies provide lucrative opportunities for sustained market expansion.
Key Features of the Study:
- This report provides in-depth analysis of the global type 1 diabetes market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global type 1 diabetes market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study includes Biocon Ltd., Novo Nordisk, Gan & Lee Pharmaceuticals, Zealand Pharma, AstraZeneca, Eli Lilly and Company, Sanofi, Wockhardt Ltd., Ypsomed AG, Novartis, Panbela Therapeutics, Diamyd Medical, Adocia, Anelixis Therapeutics, and Oramed Pharmaceuticals Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global type 1 diabetes market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global type 1 diabetes market
Detailed Segmentation-
- By Device Type:
- Insulin Pen
- Insulin Syringe
- Insulin Pump
- Insulin Jet Injectors
- By Insulin Type:
- Long-Acting Insulin
- Rapid-Acting Insulin
- By End User:
- Homecare Settings
- Hospitals & Clinics
- Academic & Research Institutes
- Others
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Biocon Ltd.
- Novo Nordisk
- Gan & Lee Pharmaceuticals
- Zealand Pharma
- AstraZeneca
- Eli Lilly and Company
- Sanofi
- Wockhardt Ltd.
- Ypsomed AG
- Novartis
- Panbela Therapeutics
- Diamyd Medical
- Adocia
- Anelixis Therapeutics
- Oramed Pharmaceuticals Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Device Type
- Market Snapshot, By Insulin Type
- Market Snapshot, By End User
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Technology Overview
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Type 1 Diabetes Market- Impact of Coronavirus (COVID-19) Pandemic
- Overall Impact
- Government Initiatives
- COVID-19 Impact on the market
5. Global Type 1 Diabetes Market, By Device Type, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Insulin Pen
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Insulin Syringe
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Insulin Pump
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Insulin Jet Injectors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
6. Global Type 1 Diabetes Market, By Insulin Type, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Long-Acting Insulin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Rapid-Acting Insulin
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
7. Global Type 1 Diabetes Market, By End User, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Homecare Settings
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Hospitals & Clinics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Academic & Research Institutes
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
8. Global Type 1 Diabetes Market, By Distribution Channel, 2019 - 2031, (USD BN)
- Overview
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)
9. Global Type 1 Diabetes Market, By Region, 2019 - 2031, (USD BN)
- Introduction
- Market Share Analysis, By Region, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, For Regions, 2020-2031
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD BN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Device Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Insulin Type, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD BN)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD BN)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profiles
- Biocon Ltd.*
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk
- Gan & Lee Pharmaceuticals
- Zealand Pharma
- AstraZeneca
- Eli Lilly and Company
- Sanofi
- Wockhardt Ltd.
- Ypsomed AG
- Novartis
- Panbela Therapeutics
- Diamyd Medical
- Adocia
- Anelixis Therapeutics
- Oramed Pharmaceuticals Inc.
11. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
